临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
S-Nitrosoglutathione
中文名称: S-亚硝基谷胱甘肽
CAS号:57564-91-7
分子式: C10H16N4O7S 分子量: 336.32
产品形式: free base
研发状态: Suspended
研发用途: Bronchopulmonary Dysplasia
研究机构: University Hospitals Cleveland Medical Center
研发日期: August 1 2024
研发阶段: Phase 1
S-nitrosoglutathione (GSNO, RVC-588, S-Nitroso-L-glutathione,Nitrosoglutathione) is an amino acid and nitric oxide donor that, under physiological conditions, spontaneously releases nitric oxide. S-nitrosoglutathione (GSNO) selectively inhibits platelet and NF-κB activation. It induces apoptosis in T cells in low concentrations (< 0.6 mM) while protecting T cells from apoptosis in higher concentrations (1-2 mM).
Phenytoin
中文名称:苯妥英
CAS号:57-41-0
分子式: C15H12N2O2 分子量: 252.27
产品形式: Free Base
研发状态: Enrolling by invitation
研发用途: Status Epilepticus
研究机构: Dhaka Medical College
研发日期: May 15 2023
研发阶段: Phase 4
Phenytoin (Di-Hydan, Dihycon, Dilabid, Diphedan, Diphenat, Diphenylan, Diphenylhydantoin, Hydantol, Lehydan, NSC 8722) is an inactive voltage-gated sodium channel stabilizer.
Irsogladine
中文名称:伊索拉定
CAS号:57381-26-7
分子式: C9H7Cl2N5 分子量: 256.09
产品形式: free base
研发状态: Completed
研发用途: Gastric Ulcer
研究机构: Boryung Pharmaceutical Co. Ltd
研发日期: April 15 2016
研发阶段: Phase 1
Irsogladine(Dicloguamine) is an anti-gastric ulcer agent that facilitates gap-junctional intercellular communication through M1 muscarininc acetylcholine receptor binding.
Ridaforolimus (Deforolimus, MK-8669)
中文名称: 息斯敏
CAS号:572924-54-0
分子式: C53H84NO14P 分子量: 990.21
产品形式: free base
研发状态: Completed
研发用途: Solid Tumors
研究机构: Merck Sharp & Dohme LLC
研发日期: Feb-12
研发阶段: Phase 1
Ridaforolimus (Deforolimus, MK-8669, AP23573) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. Phase 3.
Naftopidil
中文名称:萘哌地尔
CAS号:57149-07-2
分子式: C24H28N2O3 分子量: 392.49
产品形式: Free Base
研发状态: Completed
研发用途: Healthy
研究机构: Dong-A ST Co. Ltd.
研发日期: Sep-09
研发阶段: Phase 1
Naftopidil (KT-611) is a selective α1-adrenergic receptor antagonist with Ki of 3.7 nM, 20 nM, and 1.2 nM for α1a, α1b, and α1d, respectively, used for the treatment of benign prostatic hyperplasia.
Methenamine Hippurate
中文名称:马尿酸乌洛托品
CAS号:5714-73-8
分子式: C15H21N5O3 分子量: 319.36
产品形式: Hippurate
研发状态: Enrolling by invitation
研发用途: Recurrent Urinary Tract Infection
研究机构: University of Oslo; Amsterdam UMC location VUmc; UMC Utrecht; Göteborg University; Medical University of Lodz
研发日期: November 1 2019
研发阶段: Phase 4
Methenamine Hippurate is the hippurate salt form of methenamine, a prodrug and inactive weak base that is hydrolyzed to formaldehyde in acid urine.Methenamine Hippurate is the component of Hiprex drug which has antibacterial activity.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
